Merck Ends Development Of Two Potential COVID-19 Vaccines Over Poor Results In Early-Stage Studies
The Kenilworth, New Jersey-based drugmaker said Monday that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators.